208 related articles for article (PubMed ID: 25272292)
1. Histologic effects of medroxyprogesterone acetate on endometrioid endometrial adenocarcinoma: a Gynecologic Oncology Group study.
Zaino RJ; Brady WE; Todd W; Leslie K; Fischer EG; Horowitz NS; Mannel RS; Walker JL; Ivanovic M; Duska LR
Int J Gynecol Pathol; 2014 Nov; 33(6):543-53. PubMed ID: 25272292
[TBL] [Abstract][Full Text] [Related]
2. Coexistence of endometrial mesonephric-like adenocarcinoma and endometrioid carcinoma suggests a Müllerian duct lineage: a case report.
Yano M; Shintani D; Katoh T; Hamada M; Ito K; Kozawa E; Hasegawa K; Yasuda M
Diagn Pathol; 2019 Jun; 14(1):54. PubMed ID: 31174566
[TBL] [Abstract][Full Text] [Related]
3. Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer.
van Weelden WJ; Lalisang RI; Bulten J; Lindemann K; van Beekhuizen HJ; Trum H; Boll D; Werner HMJ; van Lonkhuijzen LRCW; Yigit R; Forsse D; Witteveen PO; Galaal K; van Ginkel A; Bignotti E; Weinberger V; Sweegers S; Kroep JR; Cabrera S; Snijders MPLM; Inda MA; Eriksson AGZ; ; Krakstad C; Romano A; van de Stolpe A; Pijnenborg JMA
Am J Obstet Gynecol; 2021 Oct; 225(4):407.e1-407.e16. PubMed ID: 34019887
[TBL] [Abstract][Full Text] [Related]
4. While women await surgery for type I endometrial cancer, depot medroxyprogesterone acetate reduces tumor glandular cellularity.
Fiascone S; Danilack VA; Kao MJ; Cohen M; Singh K; Kalife E; Luis C; Lokich E; DiSilvestro P; Robison K
Am J Obstet Gynecol; 2018 Oct; 219(4):381.e1-381.e10. PubMed ID: 30063901
[TBL] [Abstract][Full Text] [Related]
5. Up-regulation and nuclear localization of beta-catenin in endometrial carcinoma in response to progesterone therapy.
Saegusa M; Hamano M; Kuwata T; Yoshida T; Hashimura M; Akino F; Watanabe J; Kuramoto H; Okayasu I
Cancer Sci; 2003 Jan; 94(1):103-11. PubMed ID: 12708483
[TBL] [Abstract][Full Text] [Related]
6. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
Wheeler DT; Bristow RE; Kurman RJ
Am J Surg Pathol; 2007 Jul; 31(7):988-98. PubMed ID: 17592264
[TBL] [Abstract][Full Text] [Related]
7. Progestin treatment decreases CD133+ cancer stem cell populations in endometrial cancer.
Guy MS; Qamar L; Behbakht K; Post MD; Sheeder J; Sartorius CA; Spillman MA
Gynecol Oncol; 2016 Mar; 140(3):518-26. PubMed ID: 26731726
[TBL] [Abstract][Full Text] [Related]
8. A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response.
Duska LR; Filiaci VL; Walker JL; Holman LL; Hill EK; Moore RG; Ring KL; Pearl ML; Muller CY; Kushnir CL; Lankes HA; Samuelson MI; Carrick KS; Rajan A; Rodgers WH; Kohn EC; Piekarz R; Leslie KK
Clin Cancer Res; 2021 May; 27(10):2734-2741. PubMed ID: 33766814
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral effects of medroxy-progesterone on proliferation, apoptosis, and sex steroid receptors in endometrioid endometrial adenocarcinoma.
Dahmoun M; Boman K; Cajander S; Bäckström T
Gynecol Oncol; 2004 Jan; 92(1):116-26. PubMed ID: 14751147
[TBL] [Abstract][Full Text] [Related]
10. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study.
Singh M; Zaino RJ; Filiaci VJ; Leslie KK
Gynecol Oncol; 2007 Aug; 106(2):325-33. PubMed ID: 17532033
[TBL] [Abstract][Full Text] [Related]
11. Significance of p27 as a predicting marker for medroxyprogesterone acetate therapy against endometrial endometrioid adenocarcinoma.
Watanabe J; Watanabe K; Jobo T; Kamata Y; Kawaguchi M; Imai M; Okayasu I; Kuramoto H
Int J Gynecol Cancer; 2006; 16 Suppl 1():452-7. PubMed ID: 16515645
[TBL] [Abstract][Full Text] [Related]
12. Conservative treatment with progestin and pregnancy outcomes in endometrial cancer.
Hahn HS; Yoon SG; Hong JS; Hong SR; Park SJ; Lim JY; Kwon YS; Lee IH; Lim KT; Lee KH; Shim JU; Mok JE; Kim TJ
Int J Gynecol Cancer; 2009 Aug; 19(6):1068-73. PubMed ID: 19820370
[TBL] [Abstract][Full Text] [Related]
13. Six months response rate of combined oral medroxyprogesterone/levonorgestrel-intrauterine system for early-stage endometrial cancer in young women: a Korean Gynecologic-Oncology Group Study.
Kim MK; Seong SJ; Kang SB; Bae DS; Kim JW; Nam JH; Lim MC; Lee TS; Kim S; Paek J
J Gynecol Oncol; 2019 Mar; 30(2):e47. PubMed ID: 30740964
[TBL] [Abstract][Full Text] [Related]
14. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
Lax SF; Pizer ES; Ronnett BM; Kurman RJ
Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of high-dose progestin and long-term outcomes in young women with early-stage, well-differentiated endometrioid adenocarcinoma of uterine endometrium.
Park H; Seok JM; Yoon BS; Seong SJ; Kim JY; Shim JY; Park CT
Arch Gynecol Obstet; 2012 Feb; 285(2):473-8. PubMed ID: 21706284
[TBL] [Abstract][Full Text] [Related]
16. [Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].
Yu M; Shen K; Yang JX; Huang HF; Wu M; Pan LY; Lang JH; Lian LJ
Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):242-5. PubMed ID: 16759458
[TBL] [Abstract][Full Text] [Related]
17. Serial histologic observation of endometrial adenocarcinoma treated with high-dose progestin until complete disappearance of carcinomatous foci--review of more than 25 biopsies from five patients.
Kamoi S; Ohaki Y; Mori O; Kurose K; Fukunaga M; Takeshita T
Int J Gynecol Cancer; 2008; 18(6):1305-14. PubMed ID: 18217978
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices.
Reyes HD; Carlson MJ; Devor EJ; Zhang Y; Thiel KW; Samuelson MI; McDonald M; Yang S; Stephan JM; Savage EC; Dai D; Goodheart MJ; Leslie KK
Gynecol Oncol; 2016 Jan; 140(1):152-60. PubMed ID: 26524723
[TBL] [Abstract][Full Text] [Related]
19. Fertility-Sparing Approach in Patients with Endometrioid Endometrial Cancer Grade 2 Stage IA (FIGO): A Qualitative Systematic Review.
Giampaolino P; Cafasso V; Boccia D; Ascione M; Mercorio A; Viciglione F; Palumbo M; Serafino P; Buonfantino C; De Angelis MC; Verrazzo P; Grasso G; Gullo G; Bifulco G; Della Corte L
Biomed Res Int; 2022; 2022():4070368. PubMed ID: 36203482
[TBL] [Abstract][Full Text] [Related]
20. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group.
Thigpen JT; Brady MF; Alvarez RD; Adelson MD; Homesley HD; Manetta A; Soper JT; Given FT
J Clin Oncol; 1999 Jun; 17(6):1736-44. PubMed ID: 10561210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]